Detalles de la búsqueda
1.
Diagnosis and management of neuroendocrine prostate cancer.
Prostate
; 84(5): 426-440, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38173302
2.
Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial.
Lancet Oncol
; 24(10): 1094-1108, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37714168
3.
KEYNOTE-991: pembrolizumab plus enzalutamide and androgen deprivation for metastatic hormone-sensitive prostate cancer.
Future Oncol
; 2023 01 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-36705526
4.
Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial.
Lancet Oncol
; 23(3): 393-405, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-35157830
5.
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.
N Engl J Med
; 376(11): 1015-1026, 2017 03 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-28212060
6.
Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial.
J Clin Oncol
; 42(5): 571-583, 2024 Feb 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37963304
7.
Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer.
Cancer Immunol Immunother
; 62(1): 137-47, 2013 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-22865266
8.
Testing for homologous recombination repair or homologous recombination deficiency for poly (ADP-ribose) polymerase inhibitors: A current perspective.
Eur J Cancer
; 179: 136-146, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36563604
9.
Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations Identified by Testing Circulating Tumor DNA.
Clin Cancer Res
; 29(1): 92-99, 2023 01 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36318705
10.
Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study.
Eur Urol
; 83(1): 15-26, 2023 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-36055895
11.
Pembrolizumab and Enzalutamide in Patients with Abiraterone Acetate-Pretreated Metastatic Castration-Resistant Prostate Cancer: Cohort C of the Phase 1b/2 KEYNOTE-365 Study.
Eur Urol Oncol
; 2023 Nov 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37940446
12.
Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial.
J Clin Oncol
; 41(22): 3839-3850, 2023 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37290035
13.
Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib).
Clin Cancer Res
; 28(8): 1518-1530, 2022 04 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-35091440
14.
Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study.
Eur Urol
; 82(1): 22-30, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35397952
15.
Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: Further analyses from the PROfound study.
Eur J Cancer
; 170: 73-84, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35598359
16.
Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer.
NEJM Evid
; 1(9): EVIDoa2200043, 2022 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-38319800
17.
Disruption of TGF-beta signaling prevents the generation of tumor-sensitized regulatory T cells and facilitates therapeutic antitumor immunity.
J Immunol
; 183(6): 3682-9, 2009 Sep 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-19692636
18.
Depletion of tumor-induced Treg prior to reconstitution rescues enhanced priming of tumor-specific, therapeutic effector T cells in lymphopenic hosts.
Eur J Immunol
; 39(11): 3121-33, 2009 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-19839008
19.
Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study.
J Clin Oncol
; 38(5): 395-405, 2020 02 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31774688
20.
Measuring Tumor Mutational Burden (TMB) in Plasma from mCRPC Patients Using Two Commercial NGS Assays.
Sci Rep
; 9(1): 114, 2019 01 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-30643180